These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 10194081

  • 1. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups.
    Belanger F, Derouin F, Grangeot-Keros L, Meyer L.
    Clin Infect Dis; 1999 Mar; 28(3):575-81. PubMed ID: 10194081
    [Abstract] [Full Text] [Related]

  • 2. A prospective study of seroprevalence of Toxoplasmosis in general population, and in HIV/AIDS patients in Bombay, India.
    Meisheri YV, Mehta S, Patel U.
    J Postgrad Med; 1997 Mar; 43(4):93-7. PubMed ID: 10740734
    [Abstract] [Full Text] [Related]

  • 3. CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study Groups.
    Meyer L, Magierowska M, Hubert JB, Mayaux MJ, Misrahi M, Le Chenadec J, Debre P, Rouzioux C, Delfraissy JF, Theodorou I.
    J Infect Dis; 1999 Sep; 180(3):920-4. PubMed ID: 10438395
    [Abstract] [Full Text] [Related]

  • 4. A preliminary study of the frequency of focal neurological deficits in HIV/AIDS patients seropositive for Toxoplasma gondii IgG in Lagos, Nigeria.
    Oshinaike OO, Okubadejo NU, Ojini FI, Danesi MA.
    Nig Q J Hosp Med; 2010 Sep; 20(3):104-7. PubMed ID: 21033315
    [Abstract] [Full Text] [Related]

  • 5. Toxoplasmosis in HIV/AIDS patients: a current situation.
    Nissapatorn V, Lee C, Quek KF, Leong CL, Mahmud R, Abdullah KA.
    Jpn J Infect Dis; 2004 Aug; 57(4):160-5. PubMed ID: 15329448
    [Abstract] [Full Text] [Related]

  • 6. IgG anti-toxoplasma antibodies among asymptomatic HIV-infected patients in Marrakesh-Morocco.
    Addebbous A, Adarmouch L, Tali A, Laboudi M, Amine M, Aajly L, Rhajaoui M, Chabaa L, Zougaghi L.
    Acta Trop; 2012 Jul; 123(1):49-52. PubMed ID: 22425678
    [Abstract] [Full Text] [Related]

  • 7. Risk factors for toxoplasmic encephalitis in HIV-infected patients: a case-control study in Brazil.
    Nascimento LV, Stollar F, Tavares LB, Cavasini CE, Maia IL, Cordeiro JA, Ferreira MU.
    Ann Trop Med Parasitol; 2001 Sep; 95(6):587-93. PubMed ID: 11672464
    [Abstract] [Full Text] [Related]

  • 8. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S, Gona P, Dankner W, Weinberg A, Yogev R, Gershon A, Rathore M, Read JS, Huang S, Elgie C, Hudgens K, Hughes W.
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [Abstract] [Full Text] [Related]

  • 9. Incidence proportion of and risk factors for AIDS patients diagnosed with HIV dementia, central nervous system toxoplasmosis, and cryptococcal meningitis.
    Wang F, So Y, Vittinghoff E, Malani H, Reingold A, Lewis E, Giordano J, Janssen R.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jan 01; 8(1):75-82. PubMed ID: 8548350
    [Abstract] [Full Text] [Related]

  • 10. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.
    Abgrall S, Rabaud C, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV.
    Clin Infect Dis; 2001 Nov 15; 33(10):1747-55. PubMed ID: 11595976
    [Abstract] [Full Text] [Related]

  • 11. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E.
    Parassitologia; 2004 Jun 15; 46(1-2):89-93. PubMed ID: 15305694
    [Abstract] [Full Text] [Related]

  • 12. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study.
    Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M, Lazzarin A, Weber J, Clumeck N, Vetter N, Phillips A, Lundgren JD, EuroSIDA study group.
    J Infect Dis; 2006 Sep 01; 194(5):633-41. PubMed ID: 16897662
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of the IgG anti-Toxoplasma response and its avidity by western-blot in HIV-patients].
    Cristina Sarmiento M, Gómez Marín JE, Castaño Osorio JC.
    Rev Cubana Med Trop; 2005 Sep 01; 57(2):125-32. PubMed ID: 17966582
    [Abstract] [Full Text] [Related]

  • 14. [Toxoplasmosis in AIDS patients. Pathoclinical study of 78 cases].
    Hofman P, Michiels JF, Saint-Paul MC, Galibert A, Marty P, Durant J, Fuzibet JG, Mouroux J, Le Fichoux Y, Loubiere R.
    Ann Pathol; 1993 Sep 01; 13(4):233-40. PubMed ID: 8280296
    [Abstract] [Full Text] [Related]

  • 15. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
    Miro JM, Lopez JC, Podzamczer D, Peña JM, Alberdi JC, Martínez E, Domingo P, Cosin J, Claramonte X, Arribas JR, Santín M, Ribera E, GESIDA 04/98 Study Group.
    Clin Infect Dis; 2006 Jul 01; 43(1):79-89. PubMed ID: 16758422
    [Abstract] [Full Text] [Related]

  • 16. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia.
    Wang HL, Wang GH, Li QY, Shu C, Jiang MS, Guo Y.
    Acta Psychiatr Scand; 2006 Jul 01; 114(1):40-8. PubMed ID: 16774660
    [Abstract] [Full Text] [Related]

  • 17. Toxoplasma gondii antibody in HIV-infected persons.
    Sukthana Y, Chintana T, Lekkla A.
    J Med Assoc Thai; 2000 Jun 01; 83(6):681-4. PubMed ID: 10932497
    [Abstract] [Full Text] [Related]

  • 18. [Toxoplasmosis and cytomegalovirus serology in patients infected with HIV in Congo].
    Makuwa M, Loemba H, Ngouonimba J, Beuzit Y, Louis JP, Livrozet JM.
    Sante; 1994 Jun 01; 4(1):15-9. PubMed ID: 8162359
    [Abstract] [Full Text] [Related]

  • 19. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study.
    Sogaard OS, Lohse N, Gerstoft J, Kronborg G, Ostergaard L, Pedersen C, Pedersen G, Sørensen HT, Obel N.
    Clin Infect Dis; 2008 Nov 15; 47(10):1345-53. PubMed ID: 18834317
    [Abstract] [Full Text] [Related]

  • 20. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study.
    Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.